Literature DB >> 33585679

Racial and Gender Disparity in Achieving Optimal Medical Therapy for Inpatients with Peripheral Artery Disease.

Leah Gober1, Allen Bui2, Jean Marie Ruddy2.   

Abstract

Best medical therapy for peripheral artery disease (PAD) includes statin and anti-platelet agents, a combination shown to decrease rates of major cardiovascular events. Despite these findings, many patients remain undertreated and the objective of this project was to investigate the rate of initiating anti-platelet and statin therapy for inpatients newly diagnosed with PAD with a focus on disparities by race and sex. A retrospective chart review of inpatients with newly diagnosed PAD was performed between January 1, 2016 to December 31, 2016 at a single institution. Demographics and comorbid conditions were collected. Primary outcomes included antiplatelet and statin prescription at discharge. The 44 patients included in this study were predominantly male (59% vs. 41%) and African American (61% vs. 39%). Between admission and discharge, prescriptions rose from 70% to 82% for statin and 82% to 91% for anti-platelet agents. Vascular specialists were more successful than non-vascular specialists at initiating medical therapy, with statin prescriptions increasing 22% and anti-platelet prescriptions climbing 23% for those admitted to a vascular specialist. Interestingly, when the ABI was reported in the normal range, rates of statin initiation were particularly compromised at only 40%. For the total patient sample, those discharged without a statin were more commonly African American (63%) and the majority were female (67%). All patients discharged without an antiplatelet were African American and 50% were females. Despite national guidelines, patients with PAD continue to be discharged without optimal medical therapy. This study suggests that obstacles to initiation may include race, sex, admitting service, or presence of a normal ABI. Further investigation is warranted to determine effective avenues for provider education and system-wide initiatives.

Entities:  

Keywords:  Antiplatelet; Peripheral artery disease; Statin

Year:  2020        PMID: 33585679      PMCID: PMC7877491     

Source DB:  PubMed          Journal:  Ann Vasc Med Res        ISSN: 2378-9344


  36 in total

1.  Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.

Authors:  Ravi V Shah; Aferdita Spahillari; Stanford Mwasongwe; J Jeffrey Carr; James G Terry; Robert J Mentz; Daniel Addison; Udo Hoffmann; Jared Reis; Jane E Freedman; Joao A C Lima; Adolfo Correa; Venkatesh L Murthy
Journal:  JAMA Cardiol       Date:  2017-06-01       Impact factor: 14.676

2.  Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study.

Authors:  S Marlene Grenon; Eric Vittinghoff; Christopher D Owens; Michael S Conte; Mary Whooley; Beth E Cohen
Journal:  Vasc Med       Date:  2013-07-08       Impact factor: 3.239

3.  Racial differences in operation for peripheral vascular disease: results of a population-based study.

Authors:  T E Brothers; J G Robison; S E Sutherland; B M Elliott
Journal:  Cardiovasc Surg       Date:  1997-02

4.  A prediction model for polypharmacy: are older, educated women more susceptible to an adverse drug event?

Authors:  B A Perry; L W Turner
Journal:  J Women Aging       Date:  2001

5.  Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.

Authors:  Curt Diehm; Jens Rainer Allenberg; David Pittrow; Matthias Mahn; Gerhart Tepohl; Roman L Haberl; Harald Darius; Ina Burghaus; Hans Joachim Trampisch
Journal:  Circulation       Date:  2009-11-09       Impact factor: 29.690

6.  Explaining racial variation in lower extremity amputation: a 5-year retrospective claims data and medical record review at an urban teaching hospital.

Authors:  Cheryl Rucker-Whitaker; Joe Feinglass; William H Pearce
Journal:  Arch Surg       Date:  2003-12

7.  If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease.

Authors:  Brian M Renard; Milan Seth; David Share; Herb D Aronow; Eugene W Laveroni; Michele De Gregorio; Sachinder S Hans; Peter K Henke; Hitinder S Gurm; P Michael Grossman
Journal:  Vasc Med       Date:  2015-08-31       Impact factor: 3.239

8.  The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study.

Authors:  Mary McGrae McDermott; Philip Greenland; Kiang Liu; Jack M Guralnik; Lillian Celic; Michael H Criqui; Cheeling Chan; Gary J Martin; Joseph Schneider; William H Pearce; Lloyd M Taylor; Elizabeth Clark
Journal:  Ann Intern Med       Date:  2002-06-18       Impact factor: 25.391

Review 9.  Effect of lipid-lowering therapy on vasomotion and endothelial function.

Authors:  S Kinlay; J Plutzky
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 3.955

10.  Polypharmacy in African American Adults: A National Epidemiological Study.

Authors:  Shervin Assari; Hamid Helmi; Mohsen Bazargan
Journal:  Pharmacy (Basel)       Date:  2019-03-29
View more
  2 in total

1.  Socioeconomic characteristics of those with peripheral artery disease in the chronic renal insufficiency cohort.

Authors:  Jordan B Stoecker; Jordana B Cohen; Nathan Belkin; Jing C Chen; Raymond R Townsend; Dawei Xie; Harold I Feldman; Grace J Wang
Journal:  Vascular       Date:  2022-03-28       Impact factor: 1.105

2.  Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry.

Authors:  Michael H Vu; Glaiza-Mae Sande-Docor; Yulun Liu; Shirling Tsai; Mitul Patel; Chris Metzger; Mehdi H Shishehbor; Emmanouil S Brilakis; Nicolas W Shammas; Peter Monteleone; Subhash Banerjee
Journal:  J Interv Cardiol       Date:  2022-07-15       Impact factor: 1.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.